Active surveillance of localized prostate cancer.: Significance of prostate core needle biopsies

被引:0
作者
Rueschoff, J. [1 ]
Middel, P. [1 ]
Albers, P. [2 ]
机构
[1] Inst Pathol Nordhessen, D-34131 Kassel, Germany
[2] Klinikum Kassel GmbH, Urol Klin, Kassel, Germany
来源
PATHOLOGE | 2008年 / 29卷 / 05期
关键词
insignificant prostate cancer; active surveillance; Gleason score; core needle biopsy; improved pre-embedding;
D O I
10.1007/s00292-008-1013-3
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Today, more than 80% of men diagnosed with prostate cancer (PCA) by PSA screening do not die from the sequelae of their disease. About 70% present with early, organ-confined cancer and almost half of them are small (< 5 cm(3)) without evidence of progression over years (insignificant PCA). It is assumed that screening brings the diagnosis of PCA forward by about 9 years and that in almost one third of these cases immediate radical prostatectomy or radiotherapy would result in overtreatment. Thus, the treatment strategy of "active surveillance" with selective but delayed intervention for patients with organ-confined PCA could be an attractive alternative to the known curative therapy options. However, a prerequisite of such a therapeutic approach would be a precise identification of patients at high risk for cancer progression. Careful work-up of prostate core needle biopsies including improved pre-embedding preparation and detailed interpretation are of the utmost importance. A Gleason score <= 6 and tumor in only one or two cores are considered predictive of organ-confined cancer. Pathologists should concentrate on correct Gleason scoring in core needle biopsies and identification of lesions that exclude a patient from active surveillance.
引用
收藏
页码:339 / 347
页数:9
相关论文
共 39 条
[1]   20-year outcomes following conservative management of clinically localized prostate cancer [J].
Albertsen, PC ;
Hanley, JA ;
Fine, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 293 (17) :2095-2101
[2]  
AMIN MB, 2008, MOD PATHOL, V21, pA145
[3]   Overdiagnosis and overtreatment of early detected prostate cancer [J].
Bangma, C. H. ;
Roemeling, S. ;
Schroder, F. H. .
WORLD JOURNAL OF UROLOGY, 2007, 25 (01) :3-9
[4]  
BATZLER WU, 2008, KREBS DEUTSCHLAND 20
[5]  
Berney DM, 2008, MODERN PATHOL, V21, p148A
[6]   Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading [J].
Berney, Daniel M. ;
Fisher, Gabrielle ;
Kattan, Michael W. ;
Oliver, R. Timothy D. ;
Moller, Henrik ;
Fearn, Paul ;
Eastham, James ;
Scardino, Peter ;
Cuzick, Jack ;
Reuter, Victor E. ;
Foster, Christopher S. .
BJU INTERNATIONAL, 2007, 100 (06) :1240-1244
[7]   Radical prostatectomy versus watchful waiting in early prostate cancer [J].
Bill-Axelson, A ;
Holmberg, L ;
Ruutu, M ;
Häggman, M ;
Andersson, SO ;
Bratell, S ;
Spångberg, A ;
Busch, C ;
Nordling, S ;
Garmo, H ;
Palmgren, J ;
Adami, HO ;
Norlén, BJ ;
Johansson, JE .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (19) :1977-1984
[8]  
Bonkhoff H, 2005, PATHOLOGE, V26, P433, DOI 10.1007/s00292-005-0792-z
[9]   Detection of prostate cancer by α-methylacyl CoA racemase (P504S) in needle biopsy specimens previously reported as negative for malignancy [J].
Carswell, BM ;
Woda, BA ;
Wang, X ;
Li, C ;
Dresser, K ;
Jiang, Z .
HISTOPATHOLOGY, 2006, 48 (06) :668-673
[10]   Long-term outcome among men with conservatively treated localised prostate cancer [J].
Cuzick, J. ;
Fisher, G. ;
Kattan, M. W. ;
Berney, D. ;
Oliver, T. ;
Foster, C. S. ;
Moller, H. ;
Reuter, V. ;
Fearn, P. ;
Eastham, J. ;
Scardino, P. .
BRITISH JOURNAL OF CANCER, 2006, 95 (09) :1186-1194